Early-phase clinical trials inhibiting DGAT2 decreased liver fat content in patients, suggesting that DGAT2 may be effective in preventing metabolic dysfunction-associated steatohepatitis (formally known as non-alcoholic steatohepatitis) [1]. The gene discussed is DGAT2; the disease is metabolic dysfunction-associated steatohepatitis.